BPC-157 + TB-500
Sale5 mg + 5 mg · 10 mg + 10 mg
CJC-1295 without DAC + Ipamorelin
GHRH analog and pentapeptide blend
10 mg · CJC-1295 without DAC 5 mg · Ipamorelin 5 mg
This blend contains CJC-1295 without DAC, a growth hormone-releasing hormone analog, and ipamorelin, a synthetic pentapeptide. Each vial holds 5 mg of each component.
The components relate to two receptor pathways involved in growth hormone release: the GHRH pathway and the growth hormone secretagogue pathway. Ipamorelin has been studied in rat pituitary cells and animal models of hormone secretion. The CJC component has no drug affinity complex, or DAC, the modification used to bind albumin in long-acting CJC-1295.
Specifications
| Material identity | CJC-1295 without DAC + Ipamorelin |
|---|---|
| CJC-1295 without DAC | 5 mg |
| Ipamorelin | 5 mg |
| Total per vial | 10 mg |
| Component ratio | 1:1 by mass |
|---|---|
| CJC component | GHRH analog without DAC |
| Ipamorelin length | 5 amino acids |
| Ipamorelin sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
The studies describe individual components; they do not establish the effects of this blend.
Sources
- Ipamorelin pharmacology and sequence (opens in a new tab)
Ipamorelin pharmacology and sequence reference.
- Albumin-binding modification in CJC-1295 (opens in a new tab)
Peer-reviewed description of albumin-binding CJC-1295 with DAC.
SALE
$98.30Total for 1 vial
Amount per vial: 5 mg + 5 mg
- Free shipping on US orders of $275 or moreEligibility is determined at checkout. U.S. shipping only. International shipping is not offered.
For research use only.
